Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma

Fig. 1

Phenotypic difference between sunitinib-resistant and sensitive mccRCC. a Endothelial cells (HUVEC), sunitinib-sensitive Caki-1WT and sunitinib-conditioned Caki-1 DC were exposed to different concentrations of sunitinib (SUT), and cell viability was measured by MTS assay (IC50 of HUVEC = 3.322 ± 0.558, Caki-1WT = 6.699 ± 0.781 and Caki-1 DC = 16.899 ± 1.383). b Phase contrast microscopy showing changes in cell morphology between Caki-1WT and Caki-1 DC. c Western blot showing increased protein levels of β-Catenin, SOX2 and GSK-3β that suggests cancer stem-cell like properties and epithelial-to-mesenchymal characteristics of Caki-1 DC vs. Caki-1WT. d Scratch assay showing increased migration of Caki-1 DC compared to Caki-1WT. e A schematic diagram showing the indirect and direct effects of sunitinib on cancer cells. Microscopic images were taken at 5X magnification. Data are mean ± SEM and normalised to matched controls. Results are representative of three independent experiments. *p < 0.05, **p < 0.01

Back to article page